Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x100px
Document › Details

Evomedis GmbH. (11/23/23). "Press Release: Evomedis Announces Strategic Partnership with Medical University of Graz and COREMED Graz to Foster Wound Healing Innovation". Graz.

Organisations Organisation Evomedis GmbH
  Organisation 2 COREMED Graz (Cooperative Center for Regenerative Medicine / Jpanneum Research Forschungsgesellschaft mbH)
  Group Joanneum Research (Group)
Products Product EVOCellic (keratinocyte-based tissue-engineered skin substitute made from allogeneic cells)
  Product 2 EVOSens (wound dressing with non-invasive wound monitoring)
Persons Person Funk, Martin (Evomedis 202311 CEO)
  Person 2 Kaiser, Cora (Rentschler 201903– Senior Director Corp Communications before MC Services + College Hill Munich)

Investing in the future of burn medicine: Alliance to develop new cell-based therapy

EVOMEDIS GmbH (EVOMEDIS), an R&D stage life science company developing next-generation wound healing solutions, today announced the initiation of a strategic partnership with the Medical University of Graz (MedUni) and COREMED (Cooperative Center for Regenerative Medicine / JOANNEUM RESEARCH Forschungsgesellschaft mbH) to propel the shift from wound care to wound healing through innovative solutions.

EVOMEDIS has pledged an investment of €1.5 million over a span of two years for a collaborative project. The objective of this project is to develop EVOCellic, a ready-to-use wound healing solution for treating burns and chronic wounds that offers a cell-based therapy as and when the patient needs it, thereby eliminating any waiting period.

Dr. Martin Funk, CEO of EVOMEDIS, commented: “We were founded in 2020 as a spin-out from QRSKIN, a medical device company based in Würzburg, Germany, with a focus on innovative wound dressings. We have set up our operations at MedUni, which is part of the Medical Science City Graz (MSCG). This perfectly aligns with our strategy of working closely with local partners to develop new innovations for wound healing up to clinical proof-of-concept. The partnership we announced today is the next step in our strategy and will serve to deepen our cooperation with MedUni Graz, which is bolstered by the network of scientists, doctors, and research organizations of the MSCG.”

EVOCellic is a keratinocyte-based tissue-engineered skin substitute made from allogeneic cells. It has been granted Orphan Drug Designation (EU/3/22/2637) by the European Medicines Agency for the treatment of partial deep dermal and full-thickness burns. When applied to a wound, EVOCellic is designed to facilitate swift and effective healing by stimulating the skin’s natural regeneration process through the release of growth factors.

As part of the scientific collaboration, the production process for EVOCellic will be further optimized and the related pre-clinical testing performed by a team led by Prof. Lars Kamolz, Director of COREMED and Chair of the Department of Surgery. The next stage of GMP production alignment is planned to be executed at the GMP facility for new cell therapeutics (advanced therapy medicinal products, ATMPs) of the Department of Blood Group Serology and Transfusion Medicine at MedUni, led by Prof. Peter Schlenke.

About EVOCellic

EVOCellic, a storable, ready-to-use wound healing solution, is a keratinocyte-based tissue engineered skin substitute made from allogeneic cells to be applied to wounds. When applied to the wound, EVOCellic enables fast and effective healing by promoting the skin’s natural regeneration process through the release of growth factors into the wound. This allows the remaining cells to proliferate and close the wound, while also signalling for migration of more keratinocytes and fibroblasts to the wound site. EVOCellic is being developed for the treatment of deep dermal burns and chronic wounds, which affect >60 million patients in industrialized countries. EVOCellic is in preclinical development.


Based in Graz, Austria, EVOMEDIS is a research and development stage life science company with a clear vision: to shift the current paradigm from wound management to wound healing. Globally, 11 million patients require hospitalization for their burns, while another 50 million patients suffer from chronic wounds in industrialized countries. EVOMEDIS aims to address this high unmet need for chronic wound and deep second-degree burn patients with its products. EVOMEDIS was established in 2020 as a spinoff from its parent company QRSKIN and continues the development of its improved wound healing solutions (EVOSens and EVOCellic) for the European market. EVOSens combines a wound dressing with non-invasive wound monitoring for optimal support of wound healing. EVOCellic is a storable wound healing solution that delivers a cell-based therapy ready to use whenever the patient requires it without waiting time. The company’s key patent has been granted in several countries worldwide, including most EU countries, the U.S., China, Brazil, Canada, and India.

For further information, please visit and follow EVOMEDIS on LinkedIn.


Dr. Martin Funk
+43 316 228272

Media Contact
MC Services AG
Dr. Cora Kaiser
+49 89 210228 0

Record changed: 2024-01-20


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x200px

More documents for Evomedis GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px

» top